U.S. Patent No. 7,923,236 — “Fungal Enzymes”
Includes Broad Applications for Biofuels, Pulp & Paper, Waste Treatment, Textiles and Detergent Markets
JUPITER, Fla., April 27, 2011 – Dyadic International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,923,236 entitled, “Fungal Enzymes” by the United States Patent and Trademark Office (“USPTO”).
The inventions embodied by this patent relate to the use of and methods for producing novel enzymes and their combinations to convert lignocellulosic biomass into fermentable sugars. These unique enzymes degrade lignocellulosic sugars including those that provide a synergistic release of sugars from plant biomass.
The inventions also relate to methods of using novel enzymes and their combinations in a variety of other processes including the simultaneous production of organic substances such as alcohol, ethanol, amino and organic acids as well as other organic substances. Additional claims are directed to a variety of pulp and paper manufacturing processes such as biorefining, deinking and bleaching as well as for use in the treatment of waste streams and in textile and detergent processes. These enzymes were isolated from Dyadic’s patented and proprietary C1 fungus and additionally identified through the genome annotation project conducted by Dyadic in conjunction with Scripps Florida.
Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “This patent provides Dyadic with additional protection in the use of unique enzymes generated from Dyadic’s C1 platform technology to unlock the economic power of converting plentiful feedstocks of plant materials into sugars that can be fermented into chemicals, plastics, and fuels including ethanol, as a substitute for petroleum. These novel enzymes may also be applied in other industries in which Dyadic competes such as pulp and paper, waste treatment and textiles.”
This patent is the tenth U.S. patent issued to Dyadic adding to its portfolio of 74 international patents and more than 33 pending patent applications worldwide which cover various features of Dyadic’s proprietary technologies.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.
Certain statements contained in this press release are forward- looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
Dyadic International, Inc.
Adam J. Morgan
Vice President General Counsel & Business Development